DRUGS giant GSK is under scrutiny after its consumer healthcare arm was spun off for at least £10billion less than an offer it rejected. -»
GSK faces questions over Haleon's 'lower' valuation
![GSK faces questions over Haleon's 'lower' valuation]()
Reviewed by Unknown
on
19 July
Rating:
DRUGS giant GSK is under scrutiny after its consumer healthcare arm was spun off for at least £10billion less than an offer it rejected. -»
No comments:
Post a Comment